共 1038 条
[1]
Rosenwald A(2003)The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma Cancer Cell 3 185-197
[2]
Wright G(2010)Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma Int J Oncol 36 699-706
[3]
Wiestner A(2013)Landscape of somatic mutations and clonal evolution in mantle cell lymphoma Proc Natl Acad Sci U S A 110 18250-18255
[4]
Chan WC(2013)CCND2 rearrangements are the most frequent genetic events in cyclin D1(−) mantle cell lymphoma Blood. 121 1394-1402
[5]
Connors JM(2019)Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management Am J Hematol 94 710-725
[6]
Campo E(2017)Mantle cell lymphoma - current standards of care and future directions Cancer Treat Rev 58 51-60
[7]
Gascoyne RD(2009)Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909 J Clin Oncol 27 6101-6108
[8]
Grogan TM(2016)Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European mantle cell lymphoma network Lancet. 388 565-575
[9]
Muller-Hermelink HK(2005)High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine J Clin Oncol 23 7013-7023
[10]
Smeland EB(2013)A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213 Ann Oncol 24 1587-1593